Cartesian Therapeutics, Inc. Interest Expense Nonoperating
Cartesian Therapeutics, Inc. (RNAC) reported Interest Expense Nonoperating of $852.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Cartesian Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $852.00K.
- Cartesian Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $0.00.
- Cartesian Therapeutics, Inc. interest expense nonoperating for the quarter ending 2024-12-31 was $0.00.
- Cartesian Therapeutics, Inc. interest expense nonoperating for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Cartesian Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Cartesian Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $2.83M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $852.00K 10-Q · filed 2026-08-06 | $852.00K 10-Q · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $1.27M derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $1.27M derived: sum of 3 quarters · filed 2025-03-13 | $2.02M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.27M derived: sum of 2 quarters · filed 2025-03-13 | $2.02M derived: sum of 3 quarters · filed 2025-03-13 | $2.83M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.27M 10-Q · filed 2024-11-07 | $2.02M derived: sum of 2 quarters · filed 2024-11-07 | $2.83M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $752.00K 10-Q · filed 2024-08-08 | $1.56M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |